Search Results for "Lipids"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Lipids. Results 51 to 60 of 144 total matches.
Vytorin: A Combination of Ezetimibe and Simvastatin
The Medical Letter on Drugs and Therapeutics • Sep 13, 2004 (Issue 1191)
cholesterol HMG-CoA reductase inhibitors statins Zocor Zetia simvastatin ezetimibe Vytorin cholesterol Lipid ...
Vytorin, a fixed-dose combination of the cholesterol absorption inhibitor ezetimibe (Zetia - Merck/Schering Plough) and the HMG-CoA reductase inhibitor ("statin") simvastatin (Zocor - Merck), has been approved by the FDA for treatment of hypercholesterolemia. It is available as tablets containing 10 mg of ezetimibe combined with 10, 20, 40 or 80 mg of simvastatin.
Turmeric Supplements
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019 (Issue 1585)
. Effi cacy and safety of turmeric and curcumin in
lowering blood lipid levels in patients ...
Turmeric is a spice derived from the Curcuma longa
plant. Dietary supplements and foods containing
turmeric are widely promoted for relief of pain
and to improve joint mobility, immunity, digestion,
cardiovascular health, depression, anxiety, memory,
and cognition.
Voriconazole
The Medical Letter on Drugs and Therapeutics • Jul 22, 2002 (Issue 1135)
for invasive aspergillosis; it is also active against Fusarium spp.
Three lipid formulations of amphotericin B ...
Voriconazole (Vfend -- Pfizer), an antifungal triazole structurally related to fluconazole (Diflucan) with a spectrum of action similar to that of itraconazole, has been approved by the FDA for primary treatment of invasive aspergillosis and for refractory infection with Scedosporium apiospermum (the asexual form of Pseudallescheria boydii) or Fusarium spp.
Drugs for Intermittent Claudication
The Medical Letter on Drugs and Therapeutics • Feb 16, 2004 (Issue 1176)
-CoA reductase inhibitors statins hypertension ACE inhibitors ramipril Altace Exercise Lipid-lowering ...
Management of intermittent claudication, the most common symptom of peripheral arterial disease (PAD), involves both risk factor modification and symptomatic treatment (WR Hiatt, N Engl J Med 2001; 344:1608; RM Schainfeld, J Am Board Fam Pract 2001; 14:443).
Pioglitazone/Glimepiride (Duetact) for Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 29, 2007 (Issue 1253)
on serum lipids but whether the difference would result
in more favorable cardiovascular outcomes ...
Duetact (Takeda), a new fixed-dose combination of the thiazolidinedione pioglitazone (Actos) and the sulfonylurea glimepiride (Amaryl, and others), was recently approved by the FDA for treatment of type 2 diabetes. It is approved as an adjunct to diet and exercise to improve glycemic control in patients already taking pioglitazone and/or a sulfonylurea. Avandaryl, a combination of glimepiride and the thiazolidinedione rosiglitazone, was approved in 2006.
Drug Interactions with Simvastatin
The Medical Letter on Drugs and Therapeutics • Oct 20, 2008 (Issue 1297)
appropriate studies are done.
CONCLUSION — Simvastatin is a useful lipid-lowering drug that is available ...
A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin (Zocor, and others) and green tea. Since it became available generically, simvastatin has surpassed atorvastatin (Lipitor) as the best selling statin. As such, it is probably the most common cause of statin-induced myopathy, which is often a result of drug interactions.
Is Indapamide (Lozol) Safer Than A Thiazide?
The Medical Letter on Drugs and Therapeutics • Nov 17, 1989 (Issue 805)
). Adverse effects of thiazide
diuretics on glucose and lipid metabolism have been implicated ...
Recent advertisements for indapamide (Lozol - Rorer), an oral antihypertensive/diuretic (Medical Letter, 26:17, 1984), claim that the drug, unlike thiazide diuretics, does not significantly increase serum cholesterol and has a minimal impact on potassium. Indapamide has no thiazide ring but, like chlorthalidone (Hygroton; and others) and hydrochlorothiazide (HydroDiuril; and others), it does have a sulfamoyl benzamide moiety, which is probably responsible for its natriuretic and diuretic effects. Unlike the thiazides, it also has a methylindoline moiety, which apparently decreases...
Isradipine For Hypertension
The Medical Letter on Drugs and Therapeutics • May 31, 1991 (Issue 845)
beta-blockers or high doses of diuretics, isradipine does not increase serum
lipid concentrations ...
Isradipine (DynaCirc - Sandoz), a dihydropyridine calcium-channel blocker chemically related to nicardipine (Cardene) and nifedipine (Procardia, and others), was recently approved by the US Food and Drug Administration for oral treatment of hypertension.
Dehydroepiandrosterone (DHEA)
The Medical Letter on Drugs and Therapeutics • Oct 11, 1996 (Issue 985)
,
1995). Whether DHEA has any effect on body composition, fat distribution, serum lipid levels ...
Dehydroepiandrosterone (DHEA) is an adrenal androgen now being marketed as a "food supplement"in health food stores. DHEA is not approved for any indication by the US Food and Drug Administration (FDA).
In Brief: Rhabdomyolysis with Ezetimibe
The Medical Letter on Drugs and Therapeutics • Feb 28, 2005 (Issue 1203)
cholesterol lowering (Drugs for Lipids, Treat Guidel
Med Lett 2005; 3:15). The advisory did not specify ...
Health Canada, the Canadian equivalent of the FDA, recently issued a public advisory about postmarketing reports of myalgia, rhabdomyolysis, hepatitis, pancreatitis and thrombocytopenia associated with use of ezetimibe (Zetia in the US; Ezetrol in Canada). Ezetimibe is often added to a statin to increase LDL cholesterol lowering (Drugs for Lipids, Treat Guidel Med Lett 2005; 3:15). The advisory did not specify whether these patients were also taking a statin, but according to the Canadian manufacturer Merck Frosst/Schering (Merck/Schering-Plough in the US), some of the patients who developed...